Literature DB >> 21398007

Orthognathic surgery considerations for patients with undiagnosed type I osteogenesis imperfecta.

Hiroki Tashima1, Kachin Wattanawong, Cheng-Ting Ho, Ellen Wen-Ching-Ko, Anh Nguyen, Lun-Jou Lo.   

Abstract

PURPOSE: This study reports the senior author's experience of orthognathic surgery in patients with prognathism and undiagnosed type I osteogenesis imperfecta and includes a review of the literature. PATIENTS AND METHODS: Two patients with undiagnosed type I osteogenesis imperfecta underwent orthognathic surgery for correction of prognathism at Chang Gung Craniofacial Center, Taipei, Taiwan. The initial surgical plan was to perform 2-jaw orthognathic surgery in both patients.
RESULTS: The bone quality was found to be fragile during the operation, and the original plan was changed intraoperatively to 1-jaw mandibular surgery. Both operations were performed without complications, and wound healing progressed normally. Both the final facial profile and occlusal outcome were satisfactory in 1 patient, with mild relapse occurring in the second patient.
CONCLUSIONS: For patients with type I osteogenesis imperfecta, the orthognathic surgery plan should be simplified as much as possible. Prolonged intermaxillary fixation is recommended to facilitate bone union. Complications could possibly be avoided.
Copyright © 2011 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21398007     DOI: 10.1016/j.joms.2010.11.014

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  2 in total

1.  Osteogenesis imperfecta and combined orthodontics and orthognathic surgery: a case report on two siblings.

Authors:  Dong-Young Kim; Unbong Baik; Ju-Hong Jeon
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-02-26

2.  Osteogenesis imperfecta: potential therapeutic approaches.

Authors:  Maxime Rousseau; Jean-Marc Retrouvey
Journal:  PeerJ       Date:  2018-08-17       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.